Approval · Notice of Compliance 30083 · 2023
TEVA-VALACYCLOVIR: Notice of Compliance 30083
Issued February 8, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30083
- Date
- February 8, 2023
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in the standard claimed for the drug substance. Change in the specification for the drug substance
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-VALACYCLOVIR | Not yet assigned | — |
Medicinal ingredients
- VALACYCLOVIR HYDROCHLORIDE 500 MG per TAB